Akram Ansarifar

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Masoud Solaymani–Dodaran, Mostafa Ghanei, Mehdi Bagheri et al. · International Immunopharmacology · 2021 · 71 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +11

The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial

Mostafa Ghanei, Masoud Solaymani–Dodaran, Ali Qazvini et al. · Respiratory Research · 2021 · 39 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial

Masoud Solaymani Dodaran, Seyed Reza Banihashemi, Ali Es‐haghi et al. · Vaccines · 2023 · 15 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18–70 Years; A Randomized, Double-Blind Clinical Trial

Arash Mohazzab, Mohammad Hossein Fallah Mehrabadi, Ali Es‐haghi et al. · Journal of Pharmaceutical Sciences · 2023 · 15 citations

Veterinary Medicine, Immunology, Infectious Diseases +14

Cardio-metabolic and socio-demographic risk factors associated with dependency in basic and instrumental activities of daily living among older Iranian adults: Bushehr elderly health program

Kazem Khalagi, Akram Ansarifar, Noushin Fahimfar et al. · BMC Geriatrics · 2021 · 13 citations · Full text

Health Professions, Geriatric Medicine, Health Sciences +10